MedTrace Logo

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

NCT02459301 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.

Conditions

  • Gynecologic Cancer

Interventions

DRUG

IPH2201

Sponsors & Collaborators

  • Innate Pharma

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Hal Hirte · Juravinski Cancer Centre at Hamilton Health Sciences, ON Canada

  • Anna Tinker · BCCA - Vancouver Cancer Centre, BC Canada

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-17
Primary Completion
2017-11-15
Completion
2019-11-12

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459301 on ClinicalTrials.gov